NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options
Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra™, GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax®, Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL). November 23, 2009 FORT WASHINGTON, PA - Two recent FDA approvals have prompted the National Comprehensive Cance...
LUNG cancer symptoms include a cough the won ’t go away, unexplained weight loss and severe chest pain. But you could also be at risk of deadly lung tumour signs if your eyes are a distinctive colour.
While medicine transforms cancer into a chronic disease with which patients can live for an extended period of time, financial toxicity threatens to turn chronic, too.
Bradley Ryva, Keman Zhang, Abhishek Asthana, Derek Wong, Yorleny Vicioso, Reshmi Parameswaran
Elisa Boldrin, Sandro Malacrida, Enrica Rumiato, Giorgio Battaglia, Alberto Ruol, Alberto Amadori, Daniela Saggioro
Chin-Yap Loh, Aditya Arya, Ahmed Fadhil Naema, Won Fen Wong, Gautam Sethi, Chung Yeng Looi
Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Maria Letizia Motti, Maria Vincenza Carriero